NT Pharma (01011): Board Meeting Set for 31 Mar 2026 to Approve FY2025 Results and Final Dividend Proposal

Bulletin Express

Mar 18

China NT Pharma Group Company Limited (stock code: 01011) has scheduled a board meeting for Tuesday, 31 March 2026.

The agenda will cover: 1. Approval of the audited consolidated results for the financial year ended 31 December 2025. 2. Consideration of a final dividend recommendation for shareholders, if any.

The announcement was signed by Chairman Ng Tit on 18 March 2026 in Hong Kong. At the date of the notice, the Board comprises two executive directors (Ng Tit and Ng Anna Ching Mei), two non-executive directors (Dr. Qian Wei and Chin Yu), and three independent non-executive directors (Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Ng Ming Kwan).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1194903027"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194903027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194903027?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194903027","market":"hk","top_or_hot":-1,"title":"NT Pharma (01011): Board Meeting Set for 31 Mar 2026 to Approve FY2025 Results and Final Dividend Proposal","media":"Bulletin Express","content":"<p>China NT Pharma Group Company Limited (stock code: 01011) has scheduled a board meeting for Tuesday, 31 March 2026.</p>\n<p>The agenda will cover:\n1. Approval of the audited consolidated results for the financial year ended 31 December 2025.  \n2. Consideration of a final dividend recommendation for shareholders, if any.</p>\n<p>The announcement was signed by Chairman Ng Tit on 18 March 2026 in Hong Kong. At the date of the notice, the Board comprises two executive directors (Ng Tit and Ng Anna Ching Mei), two non-executive directors (Dr. Qian Wei and Chin Yu), and three independent non-executive directors (Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Ng Ming Kwan).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NT Pharma (01011): Board Meeting Set for 31 Mar 2026 to Approve FY2025 Results and Final Dividend Proposal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNT Pharma (01011): Board Meeting Set for 31 Mar 2026 to Approve FY2025 Results and Final Dividend Proposal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-18 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China NT Pharma Group Company Limited (stock code: 01011) has scheduled a board meeting for Tuesday, 31 March 2026.</p>\n<p>The agenda will cover:\n1. Approval of the audited consolidated results for the financial year ended 31 December 2025.  \n2. Consideration of a final dividend recommendation for shareholders, if any.</p>\n<p>The announcement was signed by Chairman Ng Tit on 18 March 2026 in Hong Kong. At the date of the notice, the Board comprises two executive directors (Ng Tit and Ng Anna Ching Mei), two non-executive directors (Dr. Qian Wei and Chin Yu), and three independent non-executive directors (Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Ng Ming Kwan).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01011","symbol_name":"泰凌医药","start_time":0,"source_url":"","article_id":"1194903027","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194903027","pubTimestamp":1773824516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China NT Pharma Group Company Limited (stock code: 01011) has scheduled a board meeting for Tuesday, 31 March 2026. The agenda will cover: 1. Approval of the audited consolidated results for the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01011":"泰凌医药"},"translate_title":"泰凌医药(01011)：定于2026年3月31日召开董事会批准2025财年业绩及末期股息建议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01011":1},"content_text":"China NT Pharma Group Company Limited (stock code: 01011) has scheduled a board meeting for Tuesday, 31 March 2026.\nThe agenda will cover:\n1. Approval of the audited consolidated results for the financial year ended 31 December 2025.  \n2. Consideration of a final dividend recommendation for shareholders, if any.\nThe announcement was signed by Chairman Ng Tit on 18 March 2026 in Hong Kong. At the date of the notice, the Board comprises two executive directors (Ng Tit and Ng Anna Ching Mei), two non-executive directors (Dr. Qian Wei and Chin Yu), and three independent non-executive directors (Yu Tze Shan Hailson, Dr. Zhao Yubiao, and Ng Ming Kwan).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}